First ARM2 patient included

The study ARM2 of the TNBC-MERIT clinical trial was opened in September 2017 by recommendation of the DSMB. The first patient was enrolled in October 2017 in Germany. The patient will receive the on-demand manufactured individualized cancer vaccine at the beginning of next year.